



Kaleebu, Pontiano; Levin, Jonathan; Nanvubya, Annet; Kibengo, Freddie; Jaoko, Walter; Pala, Pietro; Perreau, Matthieu; Namuniina, Annemarie; Kitandwe, Paul; Tapia, Gonzalo; Serwanga, Jennifer; Yates, Nicole; Fast, Pat; Mayer, Bryan; Montefiori, David; Tomaras, Georgia; Robb, Merlin; Lee, Carter; Wagner, Ralf; Sanders, Edward; Kilembe, William; Kiwanuka, Noah; Gilmour, Jill; Kuipers, Hester; Vooij, Dani; Chinyenze, Kundai; Priddy, Frances; Ding, Song; Hanke, Tom; Pantaleo, Giuseppe (2017) THE RESULTS OF THE EV06 DNA-PROTEIN COMBINATION TRIAL AND PLANS FOR GREAT, AN EDCTP2-FUNDED CONSERVED-MOSAIC EPITOPE HIV VACCINE TRIAL. *BMJ Global Health*, 2 (Suppl). A16.2-A16. DOI: <https://doi.org/10.1136/bmjgh-2016-000260.39>

Downloaded from: <http://researchonline.lshtm.ac.uk/4651028/>

DOI: [10.1136/bmjgh-2016-000260.39](https://doi.org/10.1136/bmjgh-2016-000260.39)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

Methods EV06 enrolled 72 males and females aged 18–45, half infected with *S. mansoni* (SM+). In each arm 30 received vaccine and 6 placebo at week 0, 4 and 24. Responses were evaluated at week 0, 6, 26 and 36. Humoral responses were measured as binding IgG against a panel of HIV-1 envelope glycoproteins and as neutralizing antibodies (Nabs), using TZM/ bl cells and tier 1 pseudoviruses. Cellular responses were measured as HIV-specific CD4+ and CD8+ T-cell by IFN- γ ELIS-pot and multi-cytokine intracellular staining flow cytometry. GREAT will be a phase IIa trial and preparation for efficacy trials in Kenya, Uganda and Zambia testing ChAdOx1.tHIVconsv5 and ChAdOx1.tHIVconsv6 followed by MVA.tHIVconsv3 and MVA.tHIVconsv4 on week 2 (Arm 1) or week 8 (Arm 2).

Progress Differences in binding IgG response rates were observed in vaccinated participants against the vaccine matched clade C V1V2 (gp70–96ZM651.02 V1V2) at week 6: 56% among SM+ versus 86% among SM – ($p=0.039$). At week 36, response magnitudes were statistically lower in the SM+ against gp120 and gp140 proteins ($p=0.04$ for both). SM+ also had lower Nabs and ELISpot responses at various time points. Still blinded data on the first 20 volunteers show 80% responders for CD4 T cell at w26 and 70% CD8 responders at w36. These trials will provide more data on challenges facing HIV vaccine development in Africa.

OA-033 **THE RESULTS OF THE EV06 DNA-PROTEIN COMBINATION TRIAL AND PLANS FOR GREAT, AN EDCTP2-FUNDED CONSERVED-MOSAIC EPI TOPE HIV VACCINE TRIAL**

Pontiano Kaleebu,¹ Jonathan Levin,¹ Annet Nanvubya,² Freddie Kibengo,¹ Walter Jaoko,³ Pietro Pala,¹ Matthieu Perreau,⁴ Annemarie Namuniina,² Paul Kitandwe,² Gonzalo Tapia,⁴ Jennifer Serwanga,¹ Nicole Yates,⁵ Pat Fast,⁶ Bryan Mayer,⁷ David Montefiori,⁵ Georgia Tomaras,⁵ Merlin Robb,⁸ Carter Lee,⁹ Ralf Wagner,¹⁰ Edward Sanders,¹¹ William Kilembe,¹² Noah Kiwanuka,² Jill Gilmour,^{6,13} Hester Kuipers,⁶ Dani Vooij,⁶ Kundai Chinyenze,⁶ Frances Priddy,⁶ Song Ding,¹⁴ Tom Hanke,¹⁵ Giuseppe Pantaleo,^{4,16} EV06 study team GREAT study team¹. ¹MRC-UVRI AIDS, Uganda; ²UVRI-IAVI HIV Vaccine Program, Uganda; ³University of Nairobi, Kenya; ⁴CHUV, Switzerland; ⁵Duke University, United States of America; ⁶IAVI, United States; ⁷Fred Hutchinson Cancer Research Center, United States of America; ⁸MHRP, United States; ⁹GSID, United States of America; ¹⁰Universität Regensburg, Germany; ¹¹KEMRI, Kenya; ¹²ZEHPR, Zambia; ¹³Imperial College London, United Kingdom; ¹⁴EuroVacc Foundation, Switzerland; ¹⁵University of Oxford, United Kingdom; ¹⁶SVRI, Switzerland

10.1136/bmjgh-2016-000260.39

Background These two trials under Europe-Africa collaborations aim at addressing two factors relevant for Africa i.e helminth infections and HIV-1 diversity. EV06 used a novel combination of DNA expressing clade C Env, Gag and Pol-nef co-administered with AIDS VAX®B/E Env protein to study the effect of *S. mansoni* on vaccine responses. GREAT is a recently awarded trial using a 2nd generation improved conserved tHIVConsvX T-cell vaccine candidate combined with bivalent mosaic design to increase breadth and protective epitopes.